TREM2 Protein (Triggering Receptor Expressed on Myeloid Cells 2)

TREM2 Protein (Triggering Receptor Expressed on Myeloid Cells 2)

Pathway Diagram

Overview

TREM2 (Triggering Receptor Expressed on Myeloid Cells 2) is a transmembrane receptor protein encoded by the TREM2 gene located on chromosome 6p21.1. This 23-kilodalton immunoreceptor is primarily expressed on the surface of myeloid cells, including microglia, macrophages, osteoclasts, and dendritic cells. TREM2 has emerged as a critical regulator of innate immune responses in the central nervous system (CNS) and has become a major focus in neurodegeneration research following the discovery of loss-of-function mutations that increase disease susceptibility.

Function/Biology

TREM2 Protein (Triggering Receptor Expressed on Myeloid Cells 2)

Pathway Diagram

Overview

TREM2 (Triggering Receptor Expressed on Myeloid Cells 2) is a transmembrane receptor protein encoded by the TREM2 gene located on chromosome 6p21.1. This 23-kilodalton immunoreceptor is primarily expressed on the surface of myeloid cells, including microglia, macrophages, osteoclasts, and dendritic cells. TREM2 has emerged as a critical regulator of innate immune responses in the central nervous system (CNS) and has become a major focus in neurodegeneration research following the discovery of loss-of-function mutations that increase disease susceptibility.

Function/Biology

TREM2 functions as a pattern recognition receptor that binds ligands including lipoproteins, phosphatidylserine, and bacterial lipopolysaccharides. The protein consists of an extracellular immunoglobulin V-domain, a transmembrane domain, and a short cytoplasmic tail. TREM2 operates as part of a signaling complex with the adaptor protein DAP12 (also called TYROBP), which contains immunoreceptor tyrosine-based activation motifs (ITAMs). This interaction is essential for downstream signaling cascade activation.

Upon ligand engagement, TREM2-DAP12 signaling recruits and activates Src family kinases, particularly Lyn and Syk, which phosphorylate downstream targets including LAT and SLP-76, ultimately activating phosphatidylinositol 3-kinase (PI3K) and mitogen-activated protein kinase (MAPK) pathways. This cascade promotes key microglial functions including phagocytosis of pathogens and cellular debris, migration toward damaged tissue, and secretion of anti-inflammatory cytokines.

Role in Neurodegeneration

TREM2 has become recognized as a major genetic risk factor for Alzheimer's disease (AD) following genome-wide association studies and functional investigations. Rare coding variants in TREM2, particularly the R47H substitution (arginine to histidine at position 47), increase AD risk approximately three-fold. Additional variants including H157Y, T96K, and Q33K have been identified with similar or greater effect sizes. Interestingly, some TREM2 mutations increase risk, while others appear protective, suggesting complex relationships between receptor function and disease susceptibility.

TREM2 dysfunction has also been implicated in frontotemporal dementia, with loss-of-function mutations causing nasu-hakola disease (also known as polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy, or PLOSL). Research indicates potential involvement in Parkinson's disease pathology, though evidence remains emerging. The protein's role in clearing amyloid-beta and other neurotoxic proteins makes it relevant across multiple neurodegenerative conditions.

Molecular Mechanisms

TREM2's contribution to neurodegeneration involves multiple complementary mechanisms. In Alzheimer's disease, TREM2 dysfunction reduces microglial phagocytic capacity, impairing clearance of amyloid-beta plaques and phosphorylated tau aggregates. This deficiency leads to increased accumulation of pathological proteins and elevated neuroinflammation characterized by dysregulated cytokine production.

TREM2 signaling also regulates microglial metabolic state and phenotype, influencing transitions between resting and activated states. Loss of TREM2 function impairs microglial response to amyloid-beta, reducing recruitment to plaques and diminishing capacity for debris clearance. Additionally, TREM2 modulates inflammatory responses; impaired TREM2 signaling can shift microglial activation toward neurotoxic pro-inflammatory profiles that exacerbate neurodegeneration.

Soluble TREM2 (sTREM2), generated through proteolytic cleavage by ADAM10 and ADAM17, serves as a biomarker in cerebrospinal fluid and blood, with altered levels observed in various neurodegenerative diseases and correlating with disease progression rates.

Clinical/Research Significance

TREM2 represents a promising therapeutic target for neurodegeneration. Strategies include TREM2 agonists to enhance receptor signaling, DAP12-based approaches to improve downstream signaling efficiency, and modulation of microglial activation states. Clinical trials investigating TREM2-targeted therapeutics are ongoing for Alzheimer's disease.

Measuring sTREM2 levels provides potential value for disease stratification, prognosis prediction, and monitoring therapeutic responses. TREM2 genetic testing may identify individuals at increased risk, enabling earlier intervention opportunities.

Related Entities

• DAP12 (TYROBP) - essential adaptor protein and signaling partner
• Microglia - primary CNS cell type expressing TREM2
• Amyloid-beta - key TREM2 ligand in Alzheimer's disease
• Tau protein - neurodegeneration-associated target of microglial clearance
• ADAM10 an

Pathway Diagram

The following diagram shows the key molecular relationships involving TREM2 Protein (Triggering Receptor Expressed on Myeloid Cells 2) discovered through SciDEX knowledge graph analysis: